Australia News

Found 7,694 articles

• Immutep Appoints Leading Oncologists to its Clinical Advisory Board

  5/18/2022

  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune diseases, announced today the appointment of four new members to the Company’s Clinical Advisory Board (CAB).

• Incannex Announces Positive Pre-IND Meeting with U.S. FDA for IHL-42X for Obstructive Sleep Apnoea

  5/17/2022

  Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: IHL), ('Incannex' or the 'Company') is pleased to announce that it completed a highly constructive Pre-Investigational New Drug Application ('pre-IND') meeting with the U.S. Food and Drug Administration ('FDA') to discuss the development IHL-42X.

• Helico Raises Seed Funding for Producing Therapeutics and Medicines in Plants

  5/17/2022

  Biopharma Helico has completed an AUD $1.8 million seed funding round, attracting international interest in its plans to produce therapeutic compounds from plants and, ultimately, ‘edible medicine’.

• Prota Therapeutics Achieves 51 Percent Peanut Allergy Remission Rate, First Company to Validate Significant Quality of Life Improvements Compared with Standard Care

  5/16/2022

  Prota Therapeutics Pty Ltd is the first company to validate significant Health-Related Quality of Life improvements, when compared to placebo, in a Phase 2b clinical trial of oral immunotherapy PRT120, in which 51 percent of treated children aged 1-10 years achieved clinical remission.

• Bionomics Limited to Participate in Upcoming Investor Conferences - May 16, 2022

  5/16/2022

  Bionomics Limited announced that Dr Errol De Souza, Executive Chairman of Bionomics, will participate in three upcoming investor conferences:

• GeneQuantum Healthcare's Two Next Generation Bioconjugate Drugs, GQ1005 and GQ1007, Have Been Approved for Clinical Trials in Australia

  5/16/2022

  GeneQuantum Healthcare Co., Ltd. announced that two of the company's bioconjugate drug candidates have won the approval for clinical trials in Australia, further enhancing GeneQuantum's pipelines in the clinical stage.

• Incannex Completes Share Sale and Purchase Agreement to Wholly Acquire APIRx Pharmaceuticals USA, LLC

  5/12/2022

  Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), ('Incannex' or the 'Company') advises that it has entered into a Share Sale and Purchase Agreement to acquire 100% of the issued share capital in APIRx Pharmaceuticals USA, LLC (APIRx) (Acquisition). 

• AVITA Medical Reports First Quarter 2022 Financial Results

  5/12/2022

  AVITA Medical, Inc. reported financial results for its first quarter ended March 31, 2022.

• Opthea To Present at Upcoming Investor Conferences - May 11, 2022

  5/11/2022

  Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that Dr Megan Baldwin, the Company’s Chief Executive Officer, will present at upcoming investor conferences in May.

• ENA Respiratory Selected for BLUE KNIGHT™ to Accelerate Development of Pan-Antiviral Nasal Spray

  5/11/2022

  ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for pan-antiviral prophylaxis in at-risk populations and pandemic preparedness, has been selected to join BLUE KNIGHT™, a joint initiative between Johnson & Johnson Innovation – JLABS (JLABS) and the Biomedical Advanced Research and Development Authority (BARDA), a component of the U.S. Department of Health and Human Services

• Immuron US DoD Naval Medical Research Center Submits IND Application for New Campylobacter ETEC Therapeutic

  5/11/2022

  Immuron Limited is pleased to announce that the US Naval Medical Research Center has submitted an Investigational New Drug application to the US Food and Drug Administration for a new oral therapeutic targeting Campylobacter and ETEC developed in collaboration with Immuron.

• Propanc Biopharma Offers a Novel Way to Stop Cancer

  5/11/2022

  Propanc Biopharma, Inc., a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced a novel way to stop cancer by inducing a process called “cell differentiation”.

• BCAL Files Foundational Patent Application

  5/11/2022

  Breast cancer screening and diagnostic company BCAL Diagnostics Limited is pleased to announce the filing of a provisional patent application number 2022901245 at IP Australia covering key lipid biomarkers that form part of its revolutionary blood-based breast cancer diagnostic.

• Incannex announces IHL-216A observed to have a neuroprotective effect in a rodent model of sports concussion; rapidly restores spatial memory post-concussion

  5/10/2022

  Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), ('Incannex" or the 'Company'), a clinical stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, today announced that IHL-216A was observed to have a strong neuroprotective effect in a widely known model of sports concussion.

• Opthea Presentation at The Retina World Congress 2022

  5/10/2022

  Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announces a presentation at the upcoming Retina World Congress 2022, taking place in Fort Lauderdale, Florida from May 12-15, 2022.

• US Department of Defense Uniformed Services University Clinical Evaluation of Travelan™

  5/9/2022

  Immuron Limited is pleased to provide shareholders and the market with a progress update on the planned clinical trial to evaluate the efficacy of Travelan® and two third party non-antibiotic products in Travelers’ Diarrhea

• Aravax appoints Dr Brett Haumann to Board of Directors

  5/6/2022

  Aravax, a clinical stage biotechnology company focused on developing the most advanced novel therapy for peanut allergy, which is designed to be safe, effective, and convenient, today announces the appointment of industry executive Dr Brett Haumann as a non-executive director to its Board of Directors.

• Immuron appoints Mr. Steven Lydeamore as Chief Executive Officer

  5/6/2022

  Immuron Limited, an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce the appointment of Steven Lydeamore as Chief Executive Officer of the Company effective 27 June 2022.

• Opthea Data for OPT-302 in Combination with Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV) Presented at ARVO 2022

  5/5/2022

  Opthea Limited announced the clinical data was presented at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting.

• Microba Accelerates Cancer Program With New Leads

  5/5/2022

  Microba Life Sciences Limited is excited to announce it has identified three therapeutic leads for the Company’s Immuno-Oncology program significantly earlier than expected.